• Citer

Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate given as fixed-dose combinations containing emtricitabine as backbones for treatment of HIV-1 infection in virologically suppressed adults: a randomised, double-blind, active-controlled phase 3 trial

par Gallant, Joel J.E.;Ward, Doug;Morales-Ramirez, Javier;Yan, Mingjin;Abram, Michael M.E.;Plummer, Andrew;Cheng, Andrew K;Rhee, Martin M.S.;Daar, Eric E.S.;Raffi, François;Brinson, Cynthia;Ruane, Peter;Dejesus, Edwin;Johnson, Margaret;Clumeck, Nathan ;Osiyemi, Olayemi
Référence The lancet. HIV, 3, 4, page (e158-e165)
Publication Publié, 2016-04

Article révisé par les pairs

• Accès en ligne
• Détails
• Contenu
• Statistiques

Titre:	Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate given as fixed-dose combinations containing emtricitabine as backbones for treatment of HIV-1 infection in virologically suppressed adults: a randomised, double-blind, active-controlled phase 3 trial
Auteur:	Gallant, Joel J.E.; Ward, Doug; Morales-Ramirez, Javier; Yan, Mingjin; Abram, Michael M.E.; Plummer, Andrew; Cheng, Andrew K; Rhee, Martin M.S.; Daar, Eric E.S.; Raffi, François; Brinson, Cynthia; Ruane, Peter; Dejesus, Edwin; Johnson, Margaret; Clumeck, Nathan; Osiyemi, Olayemi
Informations sur la publication:	The lancet. HIV, 3, 4, page (e158-e165)
Statut de publication:	Publié, 2016-04
Sujet CREF:	Généralités
Note générale:	SCOPUS: ar.j
Langue:	Anglais
Identificateurs:	urn:issn:2352-3018
	info:doi/10.1016/S2352-3018(16)00024-2
	info:pii/S2352301816000242
	info:scp/84960824872